Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme.
| dc.contributor.author | Khan, F | |
| dc.contributor.author | Ottensmeier, C | |
| dc.contributor.author | Popat, S | |
| dc.contributor.author | Dua, D | |
| dc.contributor.author | Dorey, N | |
| dc.contributor.author | Ellis, S | |
| dc.contributor.author | Szabo, M | |
| dc.contributor.author | Upadhyay, S | |
| dc.contributor.author | Califano, Raffaele | |
| dc.contributor.author | Chan, S | |
| dc.contributor.author | Lee, L | |
| dc.contributor.author | Ali, C | |
| dc.contributor.author | Nicolson, M | |
| dc.contributor.author | Bates, A | |
| dc.contributor.author | Button, M | |
| dc.contributor.author | Chaudhuri, A | |
| dc.contributor.author | Mulvenna, P | |
| dc.contributor.author | Shaw, H | |
| dc.contributor.author | Danson, S | |
| dc.date.accessioned | 2014-06-11T08:40:48Z | |
| dc.date.available | 2014-06-11T08:40:48Z | |
| dc.date.issued | 2014-04-09 | |
| dc.identifier.citation | Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. 2014: Eur J Cancer | en |
| dc.identifier.issn | 1879-0852 | |
| dc.identifier.pmid | 24726055 | |
| dc.identifier.doi | 10.1016/j.ejca.2014.03.001 | |
| dc.identifier.uri | http://hdl.handle.net/10541/320658 | |
| dc.description.abstract | Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme. | |
| dc.language | ENG | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to European journal of cancer (Oxford, England : 1990) | en |
| dc.title | Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. | en |
| dc.type | Article | en |
| dc.contributor.department | Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, United Kingdom. | en |
| dc.identifier.journal | European Journal of Cancer | en |
| html.description.abstract | Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme. |